Recent

% | $
Quotes you view appear here for quick access.

BSD Medical Corporation Message Board

  • canstic1 canstic1 Feb 9, 2010 2:44 PM Flag

    NEWS: BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer

    BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000 Hyperthermia System in Combination with Chemotherapy



    SALT LAKE CITY, February 9, 2010-BSD Medical Corporation (NASDAQ:BSDM) reports initiation of a randomized, multicenter Phase III clinical study using the BSD-2000 Hyperthermia System in combination with chemotherapy for the treatment of pancreatic cancer patients after R0/R1 surgical resection of their tumor (complete removal or only microscopic tumor remaining). The coordinating investigator is Rolf D. Issels, MD PhD, Department of Medical Oncology, Klinikum Grosshadern, Munich University Medical School, Munich, Germany. The Phase III study, which is being sponsored by the European Society for Hyperthermic Oncology (ESHO), will compare hyperthermia with chemotherapy (gemcitabine) to chemotherapy (gemcitabine) alone.

    The Phase III study was initiated following completion of a Phase II study that utilized chemotherapy and hyperthermia to treat 21 inoperable pancreatic patients who were resistant to or had failed previous chemotherapy gemcitabine treatments, a patient population with a dire prognosis. There was one complete response (complete disappearance of the tumor), 3 partial responses (more than 50% tumor reduction), and 7 patients with stable disease (no tumor growth). The study results demonstrated a low toxicity rate and an overall survival of 16.9 months. By comparison, the median survival for inoperable pancreatic cancer patients after gemcitabine treatment is only 6 months. The Phase III study, which is being sponsored by the European Society for Hyperthermic Oncology (ESHO), will compare hyperthermia with chemotherapy (gemcitabine) to chemotherapy (gemcitabine) alone.



    To view complete press release, please visit: http://bsdmedical.com/press_view.php?press_id=322


    BSD Medical Corporation

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
BSDM
0.620.0000(0.00%)Feb 24 3:59 PMEST